In 2017, Calithera Biosciences and Incyte Corporation announced a global collaboration and license agreement to jointly research, development and commercialization of Calithera’s small molecule arginase inhibitor, CB-1158 in hematology and oncology. CB-1158 is being investigated in multiple tumor types and in combination with immuno-oncology and chemotherapy medicines.